Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Pfizer Inc (PFE) vs Rivian Automotive, Inc. (RIVN) Price & Performance

Pfizer IncTrade
Rivian Automotive, Inc.Trade

Price performance (Past 24H)

Key statistics

Pfizer Inc vs Rivian Automotive, Inc. — how do they compare? Pfizer Inc trades at $27.89 (market cap $158.39B), while Rivian Automotive, Inc. trades at $16.06 (market cap $23.41B). The key difference: Pfizer Inc is far larger — about 6.8× Rivian Automotive, Inc.'s market cap, and Pfizer Inc pays a 6.19% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals.

PFERIVN
Market Cap
$158.39B$23.41B
Volume
29,869,932
Sector
HealthConsumer Cyclical
52-Week High
$29.02$22.45
52-Week Low
$23.60$12.50
Enterprise Value
$209.89B$23.45B
Dividend Yield
6.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Pfizer Inc

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Rivian Automotive, Inc.

Rivian Automotive (RIVN) trades at $16.17, up 2.73% today, with a bullish technical signal from moving averages and a consensus analyst price target of $18.70. The company shows improving financial trends, with revenue growing to $5.39 billion in 2025 and narrowing net losses, though it remains unprofitable. Recent news highlights strong R2 SUV demand and production ramp-up, but cash flow remains negative, and the CFO departure adds execution risk.

RIVN presents a high-risk, high-reward opportunity for growth investors betting on its EV market execution. Upside hinges on successful R2 scaling and path to profitability, while risks include cash burn, competition, and macroeconomic pressures on EV demand. Analyst sentiment is cautiously optimistic with 48% buy ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE

About Rivian Automotive, Inc.

Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.

Read more on RIVN